%0 Journal Article
%A Verde, Federico
%A Vávra, Jakub
%A Dorst, J.
%A Elmas, Zeynep
%A Wiesenfarth, Maximilian
%A De Gobbi, Anna
%A Ratti, Antonia
%A Poletti, Barbara
%A Tumani, Hayrettin
%A Weishaupt, Jochen
%A Silani, Vincenzo
%A Ticozzi, Nicola
%A Otto, Markus
%A Ludolph, Albert C
%A Oeckl, Patrick
%T CSF levels of the somatodendritic protein MAP2 are increased in ALS and predict shorter survival.
%J Journal of neurology, neurosurgery, and psychiatry
%V 96
%N 12
%@ 0022-3050
%C London
%I BMJ Publishing Group
%M DZNE-2025-01265
%P 1132 - 1143
%D 2025
%X Previous proteomic work has identified the somatodendritic protein MAP2 as a new candidate cerebrospinal fluid (CSF) biomarker for amyotrophic lateral sclerosis (ALS).We measured CSF levels of MAP2 and neurofilament light chain (NFL) in a retrospective cohort of 251 patients with ALS and 108 neurological controls (NCs).Patients with ALS had a higher median CSF MAP2 level compared with NCs, leading to an area under the curve (AUC) of 0.7080 (p<0.0001). They also had a higher median CSF NFL level (p<0.0001), resulting in an excellent diagnostic performance (AUC=0.9641; p<0.0001). Among patients with ALS, CSF MAP2 correlated with disease progression rate (DPR) (r=0.3099; p<0.0001) and was negatively associated with survival (HR=3.174). CSF NFL also correlated with DPR (r=0.4936; p<0.0001) and was negatively associated with survival (HR=2.759). The association of MAP2 with DPR was independent from NFL (p=0.0037). Stratifying patients based on median levels of both biomarkers resulted in significant differences in median survival times (low NFL/low MAP2, 66 months; high NFL/low MAP2 and vice versa, 35 months; high NFL/high MAP2, 26 months; p<0.0001). MAP2 was also associated with genetic status in patients with ALS, as patients with no mutations in C9ORF72 or in SOD1, as well as C9ORF72-positive ones, had higher median levels compared with NCs (p<0.0001), while patients with SOD1 mutations did not significantly differ from NCs (p>0.9999).Our study shows that the somatodendritic protein MAP2 is a promising candidate CSF biomarker for ALS.
%K Humans
%K Amyotrophic Lateral Sclerosis: cerebrospinal fluid
%K Amyotrophic Lateral Sclerosis: mortality
%K Amyotrophic Lateral Sclerosis: genetics
%K Male
%K Female
%K Middle Aged
%K Biomarkers: cerebrospinal fluid
%K Neurofilament Proteins: cerebrospinal fluid
%K Aged
%K Retrospective Studies
%K Microtubule-Associated Proteins: cerebrospinal fluid
%K Disease Progression
%K C9orf72 Protein: genetics
%K Adult
%K Superoxide Dismutase-1: genetics
%K ALS (Other)
%K CSF (Other)
%K MOTOR NEURON DISEASE (Other)
%K Biomarkers (NLM Chemicals)
%K Neurofilament Proteins (NLM Chemicals)
%K neurofilament protein L (NLM Chemicals)
%K Microtubule-Associated Proteins (NLM Chemicals)
%K MAP2 protein, human (NLM Chemicals)
%K C9orf72 Protein (NLM Chemicals)
%K Superoxide Dismutase-1 (NLM Chemicals)
%K C9orf72 protein, human (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40537251
%R 10.1136/jnnp-2025-336208
%U https://pub.dzne.de/record/282295